Emily J. Oldshue

Associate

oldshue-emily-j
  • JD, Yale Law School, 2010
  • BA, Wellesley College, 2006; Phi Beta Kappa

Qualifications

  • Massachusetts, 2010

Court Admissions

  • U.S. Supreme Court
  • National LGBT Bar Association “Best LGBT Lawyers Under 40” (2017)
  • Selected as a member of the Boston Bar Association’s 2018-2019 Public Interest Leadership Program

Emily J. Oldshue

Associate

Emily Oldshue is an associate in the capital markets group. Emily focuses primarily on advising public and private companies, investment banks and investment funds in mergers and acquisitions and private equity and capital markets transactions. Emily also advises clients on corporate governance, commercial law matters and securities law compliance and reporting. Emily represents clients in a variety of sectors, including life sciences, healthcare, technology, energy and infrastructure, manufacturing and retail.

Experience

  • Represented world’s largest asset manager in more than twenty domestic and cross-border private equity co-investment transactions across industries, including in investments in Alibaba and American Express Global Business Travel.
  • Represented a consortium of Boston hospitals in transactions involving the sale of a tri-gen power plant servicing Longwood Medical and Academic Area institutions.
  • Represented Aegerion Pharmaceuticals in its merger of equals with Novelion Therapeutics (f/k/a QLT).
  • Represented Dunkin’ Brands, the parent company of Dunkin’ Donuts and Baskin Robbins and then a portfolio company of Bain Capital, The Carlyle Group and THL Partners, in its initial public offering.
  • Represented Norcraft Companies, a portfolio company of Apax Partners and Trimaran Capital Partners, in its initial public offering.
  • Represented GC Aesthetics in its proposed initial public offering.
  • Represented Aptalis Pharma in its proposed initial public offering.
  • Represented underwriters, led by Goldman Sachs and Jefferies, in the proposed initial public offering of Autolus Therapeutics.
  • Represented underwriters, led by Morgan StanleyCowen and Company and RBC Capital Markets, in the initial public offering of Ocular Therapeutix.
  • Represented top-five global investment bank in its capacity as financial advisor to Anacor Pharmaceuticals in Anacor’s acquisition by Pfizer.
  • Represented Medtronic in a strategic portfolio sale transaction.
  • Represented National Amusements in a strategic sale transaction.
  • Represented MagneMotion in its acquisition by Rockwell Automation.
  • Represented Symmetry Surgical in its acquisition by RoundTable Healthcare Partners.
  • Represented Becton Dickinson in its acquisition of GenCell Biosystems.
  • Represented Medtronic in its acquisition of Mazor Robotics.
  • Represented Aptalis Pharma in its acquisition of Mpex Pharmaceuticals.
  • Represented AGY Holding Corp. in senior note exchange and restructuring transactions.
  • Represented Aptalis Pharma in its tender offer for its then outstanding senior notes.
  • Represented Ellucian in senior note offering in connection with investment by TPG Capital and Leonard Green & Partners.
  • Represented Wright Medical in its follow-on public offering in connection with its acquisition of Cartiva, Inc.
  • Represented Aegerion Pharmaceuticals in its follow-on public offering upon FDA approval of JUXTAPID™.
  • Represented underwriters, led by J.P. Morgan, Jefferies, Leerink Partners and BofA Merrill Lynch, in follow-on public offerings and Rule 144A convertible senior note offering by Karyopharm Therapeutics.
  • Represented Bain Capital Ventures in successive investments in Thorley Industries.
  • Represented pSivida in a follow-on public offering and in a private placement transaction with RA Capital.
  • Represented Nexant in its acquisition of substantially all of the assets of Freeman, Sullivan & Co.
Cookie Settings